Crossmark

NEO-HYPORT: does neoadjuvant radiotherapy improve breast cancer outcomes? An open label, randomised, parallel group, superiority trial to compare the disease-free survival following neoadjuvant versus adjuvant hypofractionated radiotherapy in breast cancer (NEO-HYPORT)

Crossref DOI link: https://doi.org/10.1186/s13063-026-09642-2

Published Online: 2026-04-21

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Chatterjee, Sanjoy https://orcid.org/0000-0001-7402-8645
Chakraborty, Santam

Ahmed, Rosina

Agarwal, Sanjit Kumar

Arun, Indu

Sharma, Abhishek

Maulik, Shaurav

Mahajan, Shagun
License Information

Text and Data Mining valid from 2026-04-21

Version of Record valid from 2026-06-02
More Information

Article History

Received: 7 September 2024

Accepted: 11 March 2026

First Online: 21 April 2026

Declarations

:

: Ethics approval has been obtained from the Institutional Review Board of Tata Medical Center, Kolkata. Version 1.0 of the protocol was approved on 23rd March 2024 vide approval number 2024/TMC/310/IRB814 and version 2.0 amendment was approved on 13th August 2024 vide. Approval number 2024/TMC/310/IRB814.All patients will be provided with a patient information leaflet which will detail the study purpose, procedures, harms and expected benefits. Written informed consent will be obtained and signed by an independent witness as well as the PI or Co-PI or designated authorised person(s) including trial nurses. The date, time and the name of the person obtaining the consent will be recorded in the medical records.

: The model consent form and patient information sheet for the trial is included as Appendix I. Publications from this study will not have identifying information related to patient and patient data will be reported in aggregate.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below